Partnerships, Licensing, Investments and M&A Deals and Trends for December 2013 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2013 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table Of Contents

Table of Contents

1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals and Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals and Healthcare, Global, Deal Analysis, December 2013 12
2.2 Pharmaceuticals and Healthcare, Global, Major Deals, December 2013 14
2.2.1 AstraZeneca to Acquire Remaining 50% Interest in Diabetes Joint Venture from Bristol-Myers Squibb for US$4.3 Billion 14
2.2.2 Johnson and Johnson Prices Public Offering of Notes for US$3.5 Billion 15
2.2.3 OncoMed Pharma Enters into Co-Development Agreement with Celgene 16
2.2.4 Thermo Fisher Scientific Completes Public Offering of Notes for US$3.2 Billion 17
2.2.5 Genmab Expands Licensing Agreement With Janssen Biotech 18
2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals, December 2013 19
2.4 Pharmaceuticals and Healthcare, Global, by Type, Deal Values, December 2013 20
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21
3.1 Pharmaceuticals and Healthcare, Global, MandA, December 2013 21
3.1.1 Top MandA Deals in December 2013 22
3.1.2 Pharmaceuticals and Healthcare, Global, MandA Deals by Therapy Area, July 2013 - December 2013 23
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, December 2013 24
3.2.1 Top Equity Offering Deals in December 2013 25
3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, July 2013 - December 2013 26
3.3 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, December 2013 27
3.3.1 Top PE/VC Deals in December 2013 28
3.3.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, December 2013 29
3.3.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, December 2013 30
3.3.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, July 2013-December 2013 32
3.3.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, July 2013-December 2013 33
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, December 2013 34
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, December 2013 34
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, July 2013 - December 2013 36
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), December 2013 37
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, December 2013 38
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 39
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals, July 2013 - December 2013 41
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), July 2013 - December 2013 42
4.7 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 44
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, December 2013 46
5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, December 2013 46
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2013 48
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, December 2013 49
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, December 2013 50
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, December 2013 50
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), July 2013 - December 2013 51
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), July 2013 - December 2013 53
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), July 2013 - December 2013 55
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), July 2013 - December 2013 57
6 Pharmaceuticals and Healthcare, Global, Deal Summary by Therapy Area 59
6.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, December 2013 59
6.1.1 Oncology - Deals of the Month 61
6.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, December 2013 63
6.2.1 Central Nervous System - Deals of the Month 65
6.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, December 2013 67
6.3.1 Infectious Diseases - Deals of the Month 69
6.4 Pharmaceuticals and Healthcare, Global, Metabolic Disorder Deals, December 2013 70
6.4.1 Metabolic Disorders - Deal of the Month 72
6.5 Pharmaceuticals and Healthcare, Global, Immunology Deals, December 2013 73
6.5.1 Immunology - Dealsof the Month 75
6.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, December 2013 76
6.6.1 Cardiovascular - Deal of the Month 77
6.7 Pharmaceuticals and Healthcare, Global, Respiratory, Deals, December 2013 78
6.7.1 Respiratory - Deals of the Month 79
7 Deal Summary by Geography 80
7.1 Pharmaceuticals and Healthcare, North America Deals, December 2013 80
7.1.1 North America - Deals of the Month 81
7.2 Pharmaceuticals and Healthcare, Europe, Deals, December 2013 83
7.2.1 Europe - Deals of the Month 85
7.3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, December 2013 86
7.3.1 Asia-Pacific - Deals of the Month 88
7.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, December 2013 89
7.4.1 Rest of the World - Deals of the Month 90
8 Pharmaceuticals and Healthcare, Global, Top Financial Advisors 91
8.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, MandA, July 2013 - December 2013 91
8.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, July 2013 - December 2013 93
9 Further Information 95
9.1 Methodology 95
9.2 About GlobalData 96
9.3 Disclosure information 97
9.4 Disclaimer 97



List of Tables

Table 1: Pharmaceuticals and Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 13
Table 2: Pharmaceuticals and Healthcare, Global, Major Deals, December 2013 14
Table 3: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), December 2013 20
Table 4: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 22
Table 5: Pharmaceuticals and Healthcare, Global, Top MandA Deals, December 2013 22
Table 6: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2013 - December 2013 23
Table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 25
Table 8: Pharmaceuticals and Healthcare, Global, Top Equity Offering Deals, December 2013 25
Table 9: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 26
Table 10: Pharmaceuticals and Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 28
Table 11: Pharmaceuticals and Healthcare, Global, Top PE/VC Deals, December 2013 28
Table 12: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, July 2013 - December 2013 29
Table 13: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), December 2013 31
Table 14: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 32
Table 15: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, July 2013 - December 2013 33
Table 16: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 35
Table 17: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 36
Table 18: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 37
Table 19: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), December 2013 38
Table 20: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 40
Table 21: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2013 - December 2013 43
Table 22: Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), July 2013 - December 2013 45
Table 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 47
Table 24: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 49
Table 25: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Value, December 2013 49
Table 26: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, December 2013 50
Table 27: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, December 2013 50
Table 28: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 52
Table 29: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), December 2013 54
Table 30: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2013 - December 2013 56
Table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2013 58
Table 32: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 60
Table 33: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 64
Table 34: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 68
Table 35: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 71
Table 36: Pharmaceuticals and Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 74
Table 37: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 77
Table 38: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 79
Table 39: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 81
Table 40: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 84
Table 41: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 87
Table 42: Pharmaceuticals and Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 90
Table 43: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 92
Table 44: Pharmaceuticals and Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 94


1.2 List of Figures
Figure 1: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 12
Figure 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%), December 2013 19
Figure 3: Pharmaceuticals and Healthcare, Global, Deal Values (%), December 2013 20
Figure 4: Pharmaceuticals and Healthcare, Global, MandAs, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 21
Figure 5: Pharmaceuticals and Healthcare, Global, MandAs by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2013 - December 2013 23
Figure 6: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 24
Figure 7: Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 26
Figure 8: Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 27
Figure 9: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, July 2013 - December 2013 29
Figure 10: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), December 2013 30
Figure 11: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), December 2013 31
Figure 12: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 32
Figure 13: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 34
Figure 14: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 36
Figure 15: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 37
Figure 16: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 39
Figure 17: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2013 - December 2013 41
Figure 18: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, July 2013 - December 2013 42
Figure 19: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 44
Figure 20: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 46
Figure 21: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 48
Figure 22: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 51
Figure 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), July 2013 - December 2013 53
Figure 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, July 2013 - December 2013 55
Figure 25: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), July 2013 - December 2013 56
Figure 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), December 2013 57
Figure 27: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 59
Figure 28: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 63
Figure 29: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 67
Figure 30: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 70
Figure 31: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 73
Figure 32: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 76
Figure 33: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 78
Figure 34: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 80
Figure 35: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 83
Figure 36: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 86
Figure 37: Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 89
Figure 38: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 91
Figure 39: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), July 2013 - December 2013 93

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Adalimumab  - Comprehensive patent search

Adalimumab - Comprehensive patent search

  • $ 10 118
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...

Amphotericin B  - Comprehensive patent search

Amphotericin B - Comprehensive patent search

  • $ 10 118
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...

Bemiparin sodium  - Comprehensive patent search

Bemiparin sodium - Comprehensive patent search

  • $ 10 118
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.